Longeveron (LGVN) Scheduled to Post Quarterly Earnings on Tuesday

Longeveron (NASDAQ:LGVN) is scheduled to post its quarterly earnings results after the market closes on Tuesday, May 14th. Analysts expect Longeveron to post earnings of ($2.01) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Longeveron (NASDAQ:LGVN) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($2.50) earnings per share for the quarter, missing the consensus estimate of ($2.10) by ($0.40). The company had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.21 million. Longeveron had a negative return on equity of 209.14% and a negative net margin of 3,020.17%. On average, analysts expect Longeveron to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Longeveron Stock Down 0.6 %

NASDAQ:LGVN traded down $0.01 during trading hours on Tuesday, reaching $1.67. 75,885 shares of the company traded hands, compared to its average volume of 1,528,333. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.21. The business’s 50-day moving average price is $3.27 and its two-hundred day moving average price is $10.25. Longeveron has a 1 year low of $1.60 and a 1 year high of $44.00. The stock has a market capitalization of $4.19 million, a P/E ratio of -0.16 and a beta of 0.51.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lifted their price target on Longeveron from $6.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, April 29th.

Insiders Place Their Bets

In other Longeveron news, Director Rock Soffer bought 31,915 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were acquired at an average cost of $2.35 per share, for a total transaction of $75,000.25. Following the purchase, the director now owns 208,534 shares in the company, valued at approximately $490,054.90. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Longeveron news, Director Rock Soffer acquired 31,915 shares of Longeveron stock in a transaction that occurred on Thursday, April 11th. The stock was bought at an average cost of $2.35 per share, for a total transaction of $75,000.25. Following the acquisition, the director now owns 208,534 shares of the company’s stock, valued at $490,054.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joshua Hare bought 106,383 shares of the stock in a transaction on Wednesday, April 10th. The shares were bought at an average price of $2.35 per share, for a total transaction of $250,000.05. Following the purchase, the insider now directly owns 590,727 shares in the company, valued at approximately $1,388,208.45. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 148,936 shares of company stock valued at $350,000. Insiders own 24.34% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.